Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Funda Meric-Bernstam

Showing results (251-260 of 686) with videos related to

Pageof 69
Sort By:
Cancers|August 12, 2022
Clinical Outcomes of Patients with Recurrent Microsatellite-Stable Endometrial Cancer in Early-Phase Immunotherapy Clinical TrialsJeffrey A How, Amir A Jazaeri, Siqing Fu, et al.
Breast Cancer Research and Treatment|September 14, 2007
Genetic variants in the H2AFX promoter region are associated with risk of sporadic breast cancer in non-Hispanic white women aged <or=55 yearsJiachun Lu, Qingyi Wei, Melissa L Bondy, et al.
Cancer|June 1, 2012
Impact of internal mammary lymph node drainage identified by preoperative lymphoscintigraphy on outcomes in patients with stage I to III breast cancerAmanda L Kong, Welela Tereffe, Kelly K Hunt, et al.
Cancer Cell|September 13, 2011
BikDD eliminates breast cancer initiating cells and synergizes with lapatinib for breast cancer treatmentJing-Yu Lang, Jennifer L Hsu, Funda Meric-Bernstam, et al.
Breast Cancer Research and Treatment|March 23, 2010
Among women who experience a recurrence after postmastectomy radiation therapy irradiation is not associated with more aggressive local recurrence or reduced survivalWendy A Woodward, Pauline T Truong, Tse-Kuan Yu, et al.
Cancer Discovery|September 23, 2021
Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring <i>FGF</i>/<i>FGFR</i> Aberrations: A Phase I Dose-Expansion StudyFunda Meric-Bernstam, Rastislav Bahleda, Cinta Hierro, et al.
Oncotarget|May 17, 2018
Signature program: a platform of basket trialsEric D Slosberg, Barinder P Kang, Julio Peguero, et al.
Journal of the American Medical Informatics Association : JAMIA|March 26, 2016
Extracting genetic alteration information for personalized cancer therapy from ClinicalTrials.govJun Xu, Hee-Jin Lee, Jia Zeng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 2016
High Intratumoral Stromal Content Defines Reactive Breast Cancer as a Low-risk Breast Cancer SubtypeJennifer B Dennison, Maria Shahmoradgoli, Wenbin Liu, et al.
JCO Precision Oncology|July 21, 2022
Identification of <i>KRAS</i><sup></sup> Mutations in Circulating Tumor DNA in Patients With CancerKyaw Z Thein, Amadeo B Biter, Kimberly C Banks, et al.
Pageof 69

Showing results (251-260 of 686) with videos related to

Sort By:
Pageof 69
Cancers|August 12, 2022
Clinical Outcomes of Patients with Recurrent Microsatellite-Stable Endometrial Cancer in Early-Phase Immunotherapy Clinical TrialsJeffrey A How, Amir A Jazaeri, Siqing Fu, et al.
Breast Cancer Research and Treatment|September 14, 2007
Genetic variants in the H2AFX promoter region are associated with risk of sporadic breast cancer in non-Hispanic white women aged <or=55 yearsJiachun Lu, Qingyi Wei, Melissa L Bondy, et al.
Cancer|June 1, 2012
Impact of internal mammary lymph node drainage identified by preoperative lymphoscintigraphy on outcomes in patients with stage I to III breast cancerAmanda L Kong, Welela Tereffe, Kelly K Hunt, et al.
Cancer Cell|September 13, 2011
BikDD eliminates breast cancer initiating cells and synergizes with lapatinib for breast cancer treatmentJing-Yu Lang, Jennifer L Hsu, Funda Meric-Bernstam, et al.
Breast Cancer Research and Treatment|March 23, 2010
Among women who experience a recurrence after postmastectomy radiation therapy irradiation is not associated with more aggressive local recurrence or reduced survivalWendy A Woodward, Pauline T Truong, Tse-Kuan Yu, et al.
Cancer Discovery|September 23, 2021
Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring <i>FGF</i>/<i>FGFR</i> Aberrations: A Phase I Dose-Expansion StudyFunda Meric-Bernstam, Rastislav Bahleda, Cinta Hierro, et al.
Oncotarget|May 17, 2018
Signature program: a platform of basket trialsEric D Slosberg, Barinder P Kang, Julio Peguero, et al.
Journal of the American Medical Informatics Association : JAMIA|March 26, 2016
Extracting genetic alteration information for personalized cancer therapy from ClinicalTrials.govJun Xu, Hee-Jin Lee, Jia Zeng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 2016
High Intratumoral Stromal Content Defines Reactive Breast Cancer as a Low-risk Breast Cancer SubtypeJennifer B Dennison, Maria Shahmoradgoli, Wenbin Liu, et al.
JCO Precision Oncology|July 21, 2022
Identification of <i>KRAS</i><sup></sup> Mutations in Circulating Tumor DNA in Patients With CancerKyaw Z Thein, Amadeo B Biter, Kimberly C Banks, et al.
Pageof 69